1cBio and Lee’s Pharm Partner on PARP1 Inhibitor OC-3
San Francisco, California, and Hong Kong, China, September 9, 2026 1cBio and Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm) have...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
San Francisco, California, and Hong Kong, China, September 9, 2026 1cBio and Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm) have...
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Aligos Therapeutics has received a $25 million upfront payment from Xiamen Amoytop...
SAN DIEGO, June 7, 2026 LENZ Therapeutics announced that Everest Medicines has acquired the rights to develop, manufacture, and...
